PA
ANIK icon

PharVision Advisers’s Anika Therapeutics ANIK Stock Holding History

PharVision Advisers’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-21,524
Closed -$207K – 126
2025
Q4 		$207K Sell
21,524
-19,862
-48% -$190K 0.1% 532
2025
Q3 		$389K Buy
+41,386
New +$395K 0.22% 91

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $585M AUM 5.18% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

PharVision Advisers's ANIK Position: Q1 2026 in Review

PharVision Advisers sold out of Anika Therapeutics (ANIK) in Q1 2026, closing a stake of 21,524 shares — an estimated $207K sold.

PharVision Advisers first reported a position in ANIK in Q3 2025 and held it in 2 quarters. The position peaked at $389K in Q3 2025. 130 funds tracked by Wall St. Rank hold ANIK as of Q1 2026.

  • PharVision Advisers reported no remaining Anika Therapeutics position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 21,524 Anika Therapeutics shares in Q1 2026, an estimated $207K.
  • PharVision Advisers first reported a position in Anika Therapeutics in Q3 2025 and held it in 2 quarters.
  • PharVision Advisers's Anika Therapeutics position peaked at $389K in Q3 2025.
  • 130 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.